Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in a Dose-Response Manner: Results of a Prospective Observational Study of a Strictly Controlled Population of 88,012 Subjects
Kerr et al., Regular Use of Ivermectin as Prophylaxis for COVID-19 Led Up to a 92% Reduction in COVID-19 Mortality Rate in.., Cureus, doi:10.7759/cureus.28624 (date from earlier preprint)
PSM multivariable analysis of the Itajaí trial showing significantly lower mortality with regular use of ivermectin prophylaxis. Immortal time bias may significantly affect these results.
risk of death, 92.0% lower, RR 0.08, p < 0.001, treatment 2 of 283 (0.7%), control 15 of 283 (5.3%), NNT 22, adjusted per study, strictly regular use vs. non-use, propensity score matching, multivariable.
Kerr et al., 6 Feb 2022, retrospective, propensity score matching, multivariable, Brazil, peer-reviewed, 9 authors, study period 7 July, 2020 - 2 December, 2020, dosage 200μg/kg days 1, 2, 16, 17, 0.2mg/kg/day for 2 days every 15 days.
Abstract: See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/358386329
Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90%
reduction in COVID-19 mortality rate, in a dose-response manner: definitive
results of a prospective o...
Preprint · February 2022
DOI: 10.13140/RG.2.2.20069.68320
CITATIONS
READ
0
1
9 authors, including:
Lucy Kerr
Fernando Baldi
Instituto Kerr
São Paulo State University
15 PUBLICATIONS 98 CITATIONS
431 PUBLICATIONS 4,650 CITATIONS
SEE PROFILE
SEE PROFILE
Raysildo Barbosa Lôbo
Juan Chamie
Center for Genetic Engineering and Biotechnology
Universidad EAFIT
186 PUBLICATIONS 1,196 CITATIONS
14 PUBLICATIONS 22 CITATIONS
SEE PROFILE
SEE PROFILE
Some of the authors of this publication are also working on these related projects:
Análise genômica de bovinos da raça Nelore (Bos indicus) para características quantitativas e qualitativas de carcaça e carne View project
Beth Israel work View project
All content following this page was uploaded by Cadegiani Flávio on 06 February 2022.
The user has requested enhancement of the
Strictly regular use of ivermectin as prophylaxis for COVID-19 leads to a 90%
reduction in COVID-19 mortality rate, in a dose-response manner: definitive results
of a prospective observational study of a strictly controlled 223,128 population from
a city-wide program in Southern Brazil.
Lucy Kerr, MD, ARDMS1, Fernando Baldi, PhD2, Raysildo Barbosa Lôbo, PhD3,
Washington Luiz Olivato Assagra4, Fernando Carlos Proença5, Jennifer A. Hibberd, DDS,
DPD, MRCDC6, Juan J Chamie-Quintero7, Pierre Kory, MD, MPA8, Flavio A. Cadegiani,
MD, MSc, PhD8,9*
1
Instituto Kerr de Ensino e Pesquisa, São Paulo, Brazil
Department of Animal Sciences, State University of São Paulo, São Paulo, Brazil
3
Department of Genetics, Ribeirão Preto Medical School, University of São Paulo, Ribeirão
Preto, Brazil.
4
Centro Técnico de Avaliação Genômica C.T.A.G, Ribeirão Preto, Brazil
5
Itajaí City Hall, Itajaí, Brazil
6
University of Toronto, Toronto, Canada
7
Data Analysis, Universidad EAFIT, Cambridge, USA
8
Front-Line Covid-19 Critical Care Alliance (FLCCC), USA
9
Corpometria Institute, Brasilia, Brazil
2
*Corresponding author:
Flávio A. Cadegiani, MD, MSc, PhD
Corpometria Institute
SGAS 915 Centro Clínico Advance, Rooms 260/262/264, Brasília, DF, Brazil
f.cadegiani@gmail.com, flavio.cadegiani@unifesp.br, flavio@flccc.net
+55 61 981.395.395
Key-words: COVID-19, SARS-CoV-2, ivermectin, prophylaxis, prevention,
coronavirus
Abstract
Background: Previously, we demonstrated that ivermectin use as prophylaxis for
COVID-19 was associated with reductions in COVID-19 infection, hospitalization, and
mortality rates, and in the risk of dying from COVID-19, irrespective of regularity and
accumulated use of ivermectin, in an observational, prospectively obtained data from a
strictly controlled city-wide program in a city in Southern Brazil (Itajaí, SC, Brazil) of of
medically-based, optional use of ivermectin as prophylaxis for COVID-19. In this study,
our objective was to explore the data obtained from the program to evaluate whether the
level of regularity of ivermectin use impacted in the reductions in these outcomes, aiming
to determine if ivermectin showed a progressive dose-, regularity-response in terms of
protection from COVID-19 and COVID-19 related outcomes.
Materials and methods: This is a prospective observational study..
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.